Trials / Completed
CompletedNCT01123460
Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride
Measurement of Potential Biomarkers Predicting Erlotinib Response
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 127 (actual)
- Sponsor
- ECOG-ACRIN Cancer Research Group · Network
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving erlotinib hydrochloride may help doctors learn more about the effects of erlotinib hydrochloride on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers predicting response in patients with non-small cell lung cancer previously treated with erlotinib hydrochloride.
Detailed description
OBJECTIVES: * To evaluate whether serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin can be utilized as biomarkers to predict response in patients with non-small cell lung cancer treated with erlotinib hydrochloride. OUTLINE: Serum samples are analyzed for NGAL, MMP-9, NGAL/MMP-9, and soluble E-cadherin by ELISA and Luminex assays.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | enzyme-linked immunosorbent assay | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2010-04-12
- Primary completion
- 2010-06-12
- Completion
- 2010-06-12
- First posted
- 2010-05-14
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT01123460. Inclusion in this directory is not an endorsement.